Title: Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis
Abstract: Clinical EndocrinologyVolume 74, Issue 6 p. 699-704 ORIGINAL ARTICLE Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis Ho-Yeon Chung, Ho-Yeon Chung Kyung Hee UniversitySearch for more papers by this authorSang Ouk Chin, Sang Ouk Chin Kyung Hee UniversitySearch for more papers by this authorMoo-IL Kang, Moo-IL Kang The Catholic University of KoreaSearch for more papers by this authorJung-Min Koh, Jung-Min Koh University of UlsanSearch for more papers by this authorSung-Hwan Moon, Sung-Hwan Moon Yonsei UnivresitySearch for more papers by this authorByung-Koo Yoon, Byung-Koo Yoon Sungkyunkwan UniversitySearch for more papers by this authorHyun-Koo Yoon, Hyun-Koo Yoon Kwandong UniversitySearch for more papers by this authorYoon-Sok Chung, Yoon-Sok Chung Ajou UniversitySearch for more papers by this authorHyoung-Moo Park, Hyoung-Moo Park Chung-ang University, Seoul, KoreaSearch for more papers by this author Ho-Yeon Chung, Ho-Yeon Chung Kyung Hee UniversitySearch for more papers by this authorSang Ouk Chin, Sang Ouk Chin Kyung Hee UniversitySearch for more papers by this authorMoo-IL Kang, Moo-IL Kang The Catholic University of KoreaSearch for more papers by this authorJung-Min Koh, Jung-Min Koh University of UlsanSearch for more papers by this authorSung-Hwan Moon, Sung-Hwan Moon Yonsei UnivresitySearch for more papers by this authorByung-Koo Yoon, Byung-Koo Yoon Sungkyunkwan UniversitySearch for more papers by this authorHyun-Koo Yoon, Hyun-Koo Yoon Kwandong UniversitySearch for more papers by this authorYoon-Sok Chung, Yoon-Sok Chung Ajou UniversitySearch for more papers by this authorHyoung-Moo Park, Hyoung-Moo Park Chung-ang University, Seoul, KoreaSearch for more papers by this author First published: 10 March 2011 https://doi.org/10.1111/j.1365-2265.2011.04041.xCitations: 11 Hyoung-Moo Park, Yongsan Hospital, College of Medicine, Chung-ang University, 65-207 Hangang-ro 3-ga, Yongsan-gu, Seoul 140-757, Korea. Tel.: +822 748 9969; Fax: +822 6381 9851; E-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Summary Background We performed a randomized, double-blind, prospective, 16-week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis. Methods We randomly assigned 164 adults with osteoporosis to one of two treatment groups: weekly risedronate 35 mg and cholecalciferol 5600 IU combined in a single pill (RSD+) or weekly risedronate 35 mg alone (RSD). We measured serum levels of 25(OH)D, parathyroid hormone (PTH), and bone markers and performed muscle function tests, at baseline and after 16 weeks of treatment. Results After 16 weeks of treatment, mean serum 25(OH)D increased significantly from 39·8 to 70·8 nmol/l in the RSD+ group and declined significantly from 40·5 to 35 nmol/l in the RSD group. Although both treatment groups had significant increases in serum PTH over baseline during the study, the RSD group had a significantly larger increase than the RSD+ group (13·6 vs 4·8 ng/l; P = 0·0005). In both groups, serum bone-specific alkaline phosphatase (BSAP) and C-terminal telopeptide (CTX) declined rapidly; there were no significant differences between groups. There was also no significant difference between groups in lower-extremity function tests. The overall incidence of clinical adverse events was not significantly different between groups. Conclusion In patients with osteoporosis, a once-weekly pill of risedronate and cholecalciferol provided equivalent antiresorptive efficacy to risedronate alone in terms of bone turnover and improved 25(OH)D level over a 16-week treatment period without significant adverse events. Citing Literature Volume74, Issue6June 2011Pages 699-704 RelatedInformation
Publication Year: 2011
Publication Date: 2011-05-06
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 15
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot